In response to Pfizer's cooperation with a Chinese contract pharmaceutical dealer, he is preparing to put into production Paxlovid locally. Zhejiang Huahai Pharmaceutical responded to actively cooperate with Pfizer to accelerate the work of the PAXLOD localization project.
According to the China -Singapore Jingwei report, Pfizer CEO Aberle Monday (January 9) revealed at the JP Morgan Chase Medical Care Conference held in San Francisco that Pfizer and Chinese partners were working together to prepare for it to be prepared to be in the preparation of Chinese partners and prepared to be prepared to be in the preparation.In the first half of this year, PaxLovid was produced and sold in China.
Alber did not disclose who this Chinese partner is, but the outside world believes that this partner is Zhejiang Huahai Pharmaceutical.
Some investors asked on the investor platform on Monday: "Is Huahai's current production of Pfizer's new crown (crown disease) drugs, except for cooperation in domestic cooperation in foreign markets?"
In this regard, Huahai Pharmaceutical said, "The company is actively cooperating with Pfizer to accelerate the various tasks of the localization project of the Paxlovid to ensure the sufficient supply of PaxLovid in the Chinese market and continue to meet the new crown therapy needs of Chinese patients. "
Last year, Huahai Pharmaceutical, the leader of A -share APIs, won the production agreement of Phaxlovid's preparations -Huahai Pharmaceutical will be the Pfizer in the Chinese mainland market during the agreement period (five years).Paxlovid, the cowhide therapy for Coronary Virus, provides preparation commissioned production services to meet the needs of Chinese patients.
Public information shows that Zhejiang Huahai Pharmaceutical Co., Ltd. is a company that mainly operates the production and sales of raw materials, pharmaceutical intermediates, and preparations.The company's main products include hypertension and other hypertension drugs such as Prubi and Salin.
